SURGERY PARTNERS INC (NASDAQ:SGRY) released its third-quarter 2025 financial results, revealing a mixed performance against analyst expectations. The healthcare services company, which operates a national network of surgical facilities, reported figures that fell short of revenue and earnings projections, triggering a negative market response in pre-market trading.
Third Quarter Financial Results
The company reported revenue of $821.5 million for the quarter ended September 30, 2025, falling below the analyst consensus estimate of $837.4 million. On the earnings front, the non-GAAP earnings per share came in at $0.13, which was notably lower than the estimated $0.1689 per share that market watchers had anticipated. This dual miss on both top-line and bottom-line metrics represents a significant deviation from expectations.
Key reported figures versus estimates include:
- Revenue: $821.5 million reported vs. $837.4 million estimated
- Non-GAAP EPS: $0.13 reported vs. $0.1689 estimated
Market Reaction and Recent Performance
The immediate market reaction to the earnings release has been negative. In pre-market trading, the stock is down approximately 2.74%, indicating investor disappointment with the quarterly results. This short-term drop contrasts with the stock's performance over the past month, during which it had gained nearly 8.9%. The pre-market decline suggests the earnings report has overshadowed any positive momentum the stock had built recently.
Recent stock performance highlights:
- Pre-market performance: -2.74%
- Last week's performance: -1.96%
- Last month's performance: +8.91%
Press Release Summary and Business Context
Surgery Partners announced its Q3 2025 results on November 10, 2025, reinforcing its position as a leading short-stay surgical facility owner and operator. The company's business model focuses on operating a portfolio of 161 surgical facilities, including 142 ambulatory surgery centers and 19 surgical hospitals across 31 states. These facilities specialize in non-emergency surgical procedures across various specialties such as orthopedics, ophthalmology, and gastroenterology. The press release did not include a specific financial outlook for the coming quarters, which leaves investors to rely on existing analyst estimates for future performance benchmarks.
Forward-Looking Analyst Estimates
Looking ahead, analysts have provided estimates for the company's upcoming performance. For the fourth quarter of 2025, the consensus points toward revenue of $948.6 million and earnings per share of $0.50. For the full 2025 fiscal year, expectations are set at sales of $3.42 billion with earnings per share of $0.88. These projections will serve as critical benchmarks against which investors will measure the company's future performance and strategic execution.
Analyst estimates for future periods:
- Q4 2025 Estimated Revenue: $948.6 million
- Q4 2025 Estimated EPS: $0.50
- Full Year 2025 Estimated Sales: $3.42 billion
- Full Year 2025 Estimated EPS: $0.88
For more detailed earnings information and up-to-date analyst estimates, visit the Surgery Partners earnings and estimates page.
Disclaimer: This article presents factual information based on publicly available data and should not be construed as investment advice. All investment decisions carry risk, and readers should conduct their own research or consult with a financial advisor before making any investment decisions.
